Table 1.
Clinicobiological characteristics of all patients with MPN/LPN: stratified by MPN subtype (PART I.), and LPN timing (PART II. + III.)
| PART I. | TOTAL | ET | PV | MF | MPN-U | HES |
| MPN & CLL database, n | 1475 & 8391 | 265 | 178 | 871 | 72 | 89 |
| MPN/LPN n, (%) | 34 (0.3) | 6 (1) | 8 (3) | 14 (2) | 4 (6) | 2 (2) |
| LPN type, n, (%) | ||||||
| Non-Hodgkin's lymphoma (NHL) | 17 (50) | 4 (66) | 5 (63) | 6 (43) | 2 (50) | 0 |
| Chronic lymphocytic leukemia (CLL) | 11 (33) | 2 (33) | 2 (25) | 5 (36) | 1 (25) | 1 (50) |
| Hodgkin's lymphoma (HL) | 3 (9) | 0 | 1 (12) | 1 (7) | 0 | 1 (50) |
| Multiple myeloma (MM) | 3 (9) | 0 | 0 | 2 (14) | 1 (25) | 0 |
| LPN timing, n (%) | ||||||
| First dx | 16 (49) | 0 | 2 (25) | 9 (64) | 3 (75) | 2 (100) |
| Second dx | 15 (42) | 5 (83) | 6 (75) | 3 (21) | 1 (25) | 0 |
| Simultaneous dx | 3 (9) | 1 (17) | 0 | 2 (14) | 0 | 0 |
| Sex, n (%) | ||||||
| Male | 20 (59) | 4 (67) | 5 (63) | 7 (50) | 3 (75) | 1 (50) |
| Female | 14 (41) | 2 (33) | 3 (37) | 7 (50) | 1 (25) | 1 (50) |
| Race, n (%) | ||||||
| Caucasian (Cauc) | 31 (91) | 6 (100) | 7 (88) | 12 (86) | 4 (100) | 2 (100) |
| Black (Bl) | 2 (6) | 0 | 1 (12) | 1 (7) | 0 | 0 |
| Hispanic (Hisp) | 1 (3) | 0 | 0 | 1 (7) | 0 | 0 |
| Median age at MPN dx, [range] months | 56 [16–79] | 46.5 [16–60] | 60 [45–71] | 62 [34–79] | 53 [31–55] | 64 [62–66] |
| PS, n (%) | ||||||
| 0–1 | 32 (94) | 6 (100) | 8(100) | 14 (100) | 2 (50) | 2 (100) |
| 2 | 2 (6) | 0 | 0 | 0 | 2 (50) | 0 |
| Splenomegaly, n (%) | 13 (33) | 2 (33) | 3 (38) | 8 (57) | 2 (50) | 1 (50) |
| JAK2 positive, n (%) | 14/24 (42) | 1/3 (17) | 8/8 (100) | 3/10 (21) | 2/3 (50) | 1/1 (100) |
| Abnormal karyotype, n (%) | 15 (47) | 2 (33) | 5 (63) | 6 (46) | 1 (25) | 1 (50) |
| PART II. |
LPN Prior to MPN, n=16 (47%) |
LPN After MPN, n=15 (44%) |
Simultan. LPN & MPN, n=3 (9%) |
|||
| LPN type, n, (%) | 6 NHL, 5 CLL, 3 HL, 2 MM | 1 NHL, 4 CLL, 1 MM | 1 NHL, 2 CLL | |||
| MPN type, n, (%) | 2 PV, 9 MF, 3 MPN, 2 HES | 5 ET, 6 PV, 3 MF, 1 MPN | 1 ET, 2 MF | |||
| Male/Female Ratio | 1.0 (8/8) | 2.0 (10/5) | 2.0 (2/1) | |||
| Race, n (%) | 15 Cauc, 1 Bl | 13 Cauc, 1 Bl, 1 Hisp | 3 Cauc | |||
| Median age at MPN dx, [range] months | 51.5 (34–77) | 67 (22–84) | 59 (56–72) | |||
| Median age at LPN dx, [range] months | 51 (8–76) | 53 (16–71) | 59 (56–72) | |||
| PS 2, n (%) | 0 | 2 (13) | 0 | |||
| Splenomegaly, n (%) | 5 (31) | 6 (40) | 1 (33) | |||
| JAK2 positive, n (%) | 6/10 (60) | 8/11 (72) | 1/2 (50) | |||
| Abnormal karyotype, n (%) | 6/15 (40) | 8/15 (53) | 1/3 (33) | |||
| PART III. |
LPN Prior to MPN, n=16 (47%) |
LPN After MPN, n=15 (44%) |
Simultan. LPN & MPN, n=3 (9%) |
|||
| Median time to 2nd DX, months (range) | 98 (4.7–439) | 119 (1–552) | NA | |||
| Median follow up [MPN], months, (range) | 34 (0.5–180) | 151 (91–585) | 87 (6.8–88) | |||
| Median follow up [presentation], months (range) | 36 (1–204) | 44 (2–125) | 31.8 (5.8–86) | |||
| Median observation time [1st DX], months (range) | 150 (12–470) | 151 (91–585) | 87 (6.8–88) | |||
| Median OS [MPN], months (range) | 42 (1.7–181) | 132 (78–585) | 6.8 | |||
| Median OS [LPN], months (range) | 144 (12–422) | 26 (9.4–128) | 6.8 | |||
| Overall status - Alive/Death, n (%) | 8/8 (50/50) | 6/9 (40/60) | 2/1 (67–33) | |||